NIH-Funded Clinical Trial Will Evaluate New Dengue Therapeutic

A Phase 2 clinical trial will test the safety and efficacy of an experimental treatment for dengue, a viral disease transmitted by mosquitoes.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

LJI Professor Sujan Shresta Wins New Funding to Investigate Dengue and Chikungunya Virus Vaccines

Media Type
Article
Publish or Event Date
Research Institution
La Jolla Institute for Immunology
Short Title
LJI Professor Sujan Shresta Wins New Funding
Content Coordinator
Content Manager

The Key to Fighting Viruses: Understanding Their Structure Is Vital to Unlock a Healthy Future for Humanity

Media Type
Article
Publish or Event Date
Research Institution
Purdue University
Short Title
The Key to Fighting Viruses: Understanding Their Structure Is Vital to Unlock a Healthy Future for Humanity
Content Coordinator
Content Manager

New Dengue Virus Naming System Will Help Identify and Track Variants

WashU Medicine Leads Two Major Pandemic Preparedness Research Projects

NIH Awards Establish Pandemic Preparedness Research Network

The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness network—called ReVAMPP—will focus its research efforts on “prototype pathogens,” representative pathogens from virus families known to infect humans, and high-priority pathogens that have the potential to cause deadly diseases. The pandemic preparedness research network will conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

NIAID Raises Awareness to Malaria-like Diseases in W. Africa

NIAID Now |

NIAID Raises Awareness to Malaria-like Diseases in W. Africa

Dengue, Zika, Chikungunya Viruses in Mali; Disease Likely Misdiagnosed

NIAID scientists and colleagues have identified dengue, Zika and chikungunya viruses in the West African country of Mali, where health care providers likely misdiagnose patients with illness from those viruses due to unavailable diagnostic tools. Because malaria is the most common fever-causing illness in rural sub-Saharan Africa, most medical workers presume patients with a fever have malaria. The primary cause of all four infectious diseases is a mosquito bite.

Records from the Malian Health Information System show that about one-third of all patient visits to health care facilities are related to malaria, with 2.37 million clinical cases.

A new study from NIAID’s Rocky Mountain Laboratories and the University of Sciences, Techniques and Technologies in Mali aims to help spread information to medical workers about the existence of the additional viral diseases. Ideally, circulating the information will help them obtain the necessary diagnostics.

The study, published in The American Journal of Tropical Medicine and Hygiene, involved 600 residents, 200 from each of the southern Malian communities of Soromba, Bamba and Banzana. The scientists detected antibodies to dengue virus in the blood of 77.2% of the residents tested; to Zika virus in 31.2%, and to chikungunya virus in 25.8%. They detected at least one of the three viruses in 84.9% of participants, meaning just 15.1% tested negative to any of the three viruses.

Evidence of the parasites that cause malaria was found in 44.5% of those tested. Unlike malaria, however, where most cases are found in children under age 14, residents over age 50 were most likely to have been exposed to dengue, Zika or chikungunya viruses. 

“Despite the high exposure risk to dengue virus in southern Mali, dengue fever cases have rarely been reported,” the researchers write. “This is likely due to the lack of diagnostic testing and the biased clinical focus on malaria in the region. Awareness of dengue virus as a cause of febrile illness needs to be urgently established in medical communities as an important public health measure.”

The scientists are hoping data from a more in-depth clinical study that just ended will provide additional details about the prevalence of these viruses in Mali. They also are planning to examine patients who have undiagnosed fevers to establish infection rates.

NIAID scientists are investigating dengue, Zika and chikungunya viruses to try and develop preventive and therapeutic treatment options, none of which exist.

Reference: S Bane, et alSeroprevalence of Arboviruses in a Malaria Hyperendemic Area in Southern MaliThe American Journal of Tropical Medicine and Hygiene DOI: 10.4269/ajtmh.23-0803 (2024).

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections

Media Type
Article
Publish or Event Date
Research Institution
University of Pittsburgh School of Public Health
Short Title
New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
Content Coordinator

National and Regional Biocontainment Research Facilities

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

Diagnostics Development Services

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.